

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



吉林省輝南長龍生化藥業股份有限公司

Jilin Province Huinan Changlong Bio-pharmacy Company Limited

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8049)

**DELAY IN PUBLICATION OF AUDITED ANNUAL RESULTS
FOR THE YEAR ENDED 31 DECEMBER 2019
AND DESPATCH OF THE ANNUAL REPORT**

Reference is made to the announcement of Jilin Province Huinan Changlong Bio-pharmacy Company Limited (the “**Company**”) and its subsidiaries (the “**Group**”) dated 31 March 2020 in relation to unaudited annual results of the Group for the year ended 31 December 2019. As disclosed in the above announcement, the auditing process for the annual results of the Group for the year ended 31 December 2019 has not been completed due to the restrictions in force in parts of China to combat the outbreak of COVID-19.

The board of directors (the “**Board**”) of the Company announces that upon discussion with the external independent auditor of the Company and comprehensive consideration of the auditing progress of the audited annual results of the Group for the year ended 31 December 2019 and the 2019 annual report, the Company is applying for a further time extension of the publication of the audited annual results and the 2019 annual report as the external independent auditor of the Company requires additional time to complete the relevant auditing process.

The Company expects that the auditing process will be completed on or before 8 June 2020, and the audited annual results of the Group for the year ended 31 December 2019 and the 2019 annual report will be published and/or despatched on or before 9 June 2020. The Company will issue further announcement as when necessary if there are other material developments in the completion of the auditing process, publication of the audited annual results for the year ended 31 December 2019 and despatch of the 2019 annual report.

By order of the Board
Jilin Province Huinan Changlong Bio-pharmacy Company Limited
Zhang Hong
Chairman

Jilin, the PRC
15 May 2020

As at the date of this announcement, the Board comprises six executive directors, being Zhang Hong, Zhang Xiao Guang, Zhao Bao Gang, Wu Guo Wen, Zhang Yi and Xu Xiang Fu and three independent non-executive directors, being Gao Yong Cai, Gao Qi Pin and Tian Jie.

This announcement, for which the directors of the Jilin Province Huinan Changlong Bio-pharmacy Company Limited collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to Jilin Province Huinan Changlong Bio-pharmacy Company Limited. The directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (1) the information contained in this announcement is accurate and complete in all material respects and not misleading; (2) there are no other matters the omission of which would make any statement in this announcement misleading; and (3) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.

This announcement will remain on the GEM website at www.hkgem.com on the “Latest Company Announcements” page for 7 days from the day of its posting.